These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34214886)

  • 1. The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome.
    Scuron MD; Fay BL; Connell AJ; Oliver J; Smith PA
    Int Immunopharmacol; 2021 Sep; 98():107904. PubMed ID: 34214886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
    Nayar S; Campos J; Smith CG; Iannizzotto V; Gardner DH; Colafrancesco S; Pipi E; Kollert F; Hunter KJ; Brewer C; Buckley CD; Bowman SJ; Priori R; Valesini G; Juarez M; Fahy WA; Fisher BA; Payne A; Allen RA; Barone F
    Ann Rheum Dis; 2019 Feb; 78(2):249-260. PubMed ID: 30472652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of AS2819899, a novel selective PI3Kδ inhibitor, in a NZB/W F1 mouse lupus-like nephritis model.
    Kaneko Y; Fukahori H; Yamagami K; Kawashima T; Ito M; Akamatsu M; Marui T; Kato K; Takahashi F; Morokata T
    Int Immunopharmacol; 2020 Oct; 87():106764. PubMed ID: 32736191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artesunate inhibits Sjögren's syndrome-like autoimmune responses and BAFF-induced B cell hyperactivation via TRAF6-mediated NF-κB signaling.
    Zhan T; Wang B; Fu J; Shao Y; Ye L; Shi H; Zheng L
    Phytomedicine; 2021 Jan; 80():153381. PubMed ID: 33086170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
    Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
    Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay.
    Nordmark G; Rorsman F; Rönnblom L; Cajander S; Taussig MJ; Kämpe O; Winqvist O
    Clin Exp Rheumatol; 2003; 21(1):49-56. PubMed ID: 12673889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.
    Groom J; Kalled SL; Cutler AH; Olson C; Woodcock SA; Schneider P; Tschopp J; Cachero TG; Batten M; Wheway J; Mauri D; Cavill D; Gordon TP; Mackay CR; Mackay F
    J Clin Invest; 2002 Jan; 109(1):59-68. PubMed ID: 11781351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
    Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
    Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ro/SS-A and La/SS-B antibody level variation in patients with Sjögren's syndrome and systemic lupus erythematosus.
    Wahren M; Tengnér P; Gunnarsson I; Lundberg I; Hedfors E; Ringertz NR; Pettersson I
    J Autoimmun; 1998 Feb; 11(1):29-38. PubMed ID: 9480721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
    Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
    Front Immunol; 2019; 10():2512. PubMed ID: 31708928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome.
    Fragoulis GE; Vakrakou AG; Papadopoulou A; Germenis A; Kanavakis E; Moutsopoulos HM; Manoussakis MN
    J Autoimmun; 2015 Jan; 56():12-22. PubMed ID: 25228497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases.
    Gupta S; Tatouli IP; Rosen LB; Hasni S; Alevizos I; Manna ZG; Rivera J; Jiang C; Siegel RM; Holland SM; Moutsopoulos HM; Browne SK
    Arthritis Rheumatol; 2016 Jul; 68(7):1677-87. PubMed ID: 26815287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosemantics guided gene expression profiling of Sjögren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
    Shah NR; Noll BD; Stevens CB; Brennan MT; Mougeot FB; Mougeot JC
    Arthritis Res Ther; 2017 Aug; 19(1):192. PubMed ID: 28818099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
    Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
    Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
    Narain S; Berman N; Furie R
    Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice.
    Maier-Moore JS; Horton CG; Mathews SA; Confer AW; Lawrence C; Pan Z; Coggeshall KM; Farris AD
    Arthritis Rheumatol; 2014 Sep; 66(9):2521-31. PubMed ID: 24891301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-NuMA antibodies: clinical associations and significance in patients with primary Sjögren's syndrome or systemic lupus erythematosus.
    Arcani R; Bertin D; Bardin N; Mazodier K; Jean R; Suchon P; Venton G; Daumas A; Jean E; Villani P; Kaplanski G; Jarrot PA
    Rheumatology (Oxford); 2021 Sep; 60(9):4074-4084. PubMed ID: 33404653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
    Ebo D; DeClerck LS; Bridts CH; Stevens WJ
    In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.
    Szabó K; Papp G; Szántó A; Tarr T; Zeher M
    Clin Exp Immunol; 2016 Jan; 183(1):76-89. PubMed ID: 26358223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.